bevacizumab [Avastin](Roche / Genentech)은 Pancreatic Cancer 표적 항체로, Non-Squamous Non-Small Cell Lung Cancer 영역에서 개발·상용화 중입니다. 작용기전: binds to the IKK complex (IKKα/IKKβ) to stabilize it, inhibit IKKβ activation and P65 phosphorylation, and block the canonical NF-κB signaling pathway. FDA 승인 또는 승인 단계 프로그램입니다. 대표 임상 효능: ORR 83% (ClinicalTrials.gov NCT00296816). 차별점: novel formulation was assessed for physicochemical parameters such as particle size, zeta potential, entrapment efficiency, a.
Pancreatic Cancer
Non-Squamous Non-Small Cell Lung Cancer
Active
ADC YL205 in heavily pretreated platinum-resistant ovarian canc
at
linker-payload technologies
humanized monoclonal antibody, functions as an anti-angiogenic agent by selectively binding to all soluble is
novel formulation was assessed for physicochemical parameters such as particle size, zeta potential, entrapment efficiency, a
binds to the IKK complex (IKKα/IKKβ) to stabilize it, inhibit IKKβ activation and P65 phosphorylation, and block the canonical NF-κB signaling pathway
apoptosis, metastasis, and angiogenesis
biomarkers for predicting treatment response and resistance to bevacizumab in cancer
resistance to bevacizumab in cancer
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
bevacizumab [Avastin](Roche / Genentech)은 Pancreatic Cancer 표적 항체로, Non-Squamous Non-Small Cell Lung Cancer 영역에서 개발·상용화 중입니다. 작용기전: binds to the IKK complex (IKKα/IKKβ) to stabilize it, inhibit IKKβ activation and P65 phosphorylation, and block the canonical NF-κB signaling pathway. FDA 승인 또는 승인 단계 프로그램입니다. 대표 임상 효능: ORR 83% (ClinicalTrials.gov NCT00296816). 차별점: novel formulation was assessed for physicochemical parameters such as particle size, zeta potential, entrapment efficiency, a.
Pancreatic Cancer
Non-Squamous Non-Small Cell Lung Cancer
Active
ADC YL205 in heavily pretreated platinum-resistant ovarian canc
at
linker-payload technologies
humanized monoclonal antibody, functions as an anti-angiogenic agent by selectively binding to all soluble is
novel formulation was assessed for physicochemical parameters such as particle size, zeta potential, entrapment efficiency, a
binds to the IKK complex (IKKα/IKKβ) to stabilize it, inhibit IKKβ activation and P65 phosphorylation, and block the canonical NF-κB signaling pathway
apoptosis, metastasis, and angiogenesis
biomarkers for predicting treatment response and resistance to bevacizumab in cancer
resistance to bevacizumab in cancer
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.